SUBSCRIBE
SUBSCRIBE

Novartis

NEWS
Drug Development
Novartis Drug Revolade Shows Long-Term Disease Control for Chronic/Persistent Immune Thrombocytopenia (ITP)
The long term study results were published online in Blood.
October 18, 2017
 · 
14 min read
Business
450 Jobs Eliminated as Novartis Shuts Down Colorado Facility
Novartis is closing its generic-drug manufacturing facility in Broomfield, Colo., which will cut 450 jobs over two years.
October 17, 2017
 · 
3 min read
 · 
Mark Terry
Novartis to Hold On to Its 33% Stake in Roche—For Now
Deals
Novartis AG to Hold On to Its 33% Stake in Roche—For Now
October 12, 2017
 · 
2 min read
Novartis to Hold On to Its 33% Stake in Roche—For Now
Business
Novartis AG Launches R&D Center on UC Berkeley’s Campus to Tackle ‘Undruggable’ Diseases
September 28, 2017
 · 
2 min read
Novartis to Hold On to Its 33% Stake in Roche—For Now
Deals
Novartis AG Rumored to Have Approached This $2.6 Billion Radiopharma Firm
September 28, 2017
 · 
2 min read
Interview Insider: Tips on How to Get Hired From Novartis
BioForest
Interview Insider: Tips on How to Get Hired From Novartis AG
Let’s take a look at one of the top international pharmaceutical companies in the world, Novartis.
September 26, 2017
 · 
5 min read
Incoming Novartis AG CEO Lays Out 'Productivity Revolution' Quest in First Interview
Business
Incoming Novartis AG CEO Lays Out ‘Productivity Revolution’ Quest in First Interview
September 26, 2017
 · 
2 min read
Novartis AG’ 475,000 CAR-T Drug Price Comes Under Fire
September 22, 2017
 · 
1 min read
Novartis Unloads Former New York Space for $18 Million, Resold for $30 Million
Deals
Novartis AG Unloads Former New York Space for $18 Million, Resold for $30 Million
September 15, 2017
 · 
2 min read
Load More
AWARDS
  • 2022 Best Places to Work
  • 2024 Best Places to Work
JOBS
IN THE PRESS
Press Releases
Novartis receives European Commission approval for Itvisma® for spinal muscular atrophy (SMA)
July 2, 2026
 · 
7 min read
Press Releases
Antares Therapeutics Enters Agreement with Novartis to Discover, Develop and Commercialize First-in-Class Cancer Therapies
June 24, 2026
 · 
2 min read
Press Releases
Novartis Canada and SP Quebec Celebrate 16 Years of Partnership Through Annual MS Tri-Challenge Fundraiser
June 24, 2026
 · 
4 min read
Press Releases
FiberSense Continuous Glucose Monitoring (CGM) System obtains CE mark as commercial launch preparations begin
June 17, 2026
 · 
2 min read
Press Releases
Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)
June 12, 2026
 · 
11 min read
Press Releases
Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint
June 11, 2026
 · 
8 min read
Press Releases
Orionis Biosciences Announces Strategic Collaboration with Novartis to Discover and Develop Molecular Glue Medicines
June 10, 2026
 · 
2 min read
Press Releases
Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026
June 8, 2026
 · 
6 min read
Press Releases
Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 years
June 4, 2026
 · 
11 min read
Press Releases
Novartis Cosentyx® PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patients
June 4, 2026
 · 
10 min read
Load More